Sequenom Inc News Today

A consequence (predominantly negative) of the Supreme Court's recent foray into defining (however inadequately) the contours of patent-eligible subject matter is to give the district...

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The

/PRNewswire/ -- The "Auto-Immune Diseases Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies,...

Recently Judge Connolly, Chief Judge of the District Court of Delaware had an opportunity of deciding three motions for summary judgment filed by CareDX in its litigation with Natera, Natera, Inc. v....

The U.S. Supreme Court today denied the petition for certiorari brought by CareDX, Inc.in May asking it to review a 2022 decision holding certain claims of its patents directed to detection levels of donor cell-free DNA (cfDNA) in the blood of an organ transplant patient patent ineligible.

Should the recent bill entitled the Patent Eligibility Restoration Act of 2023 (PERA) become law, it would override the existing jurisprudence and redefine which inventions are eligible...

/PRNewswire/ -- The "SNP Genotyping and Analysis: Global Strategic Business Report" report has been added to ResearchAndMarkets.coms offering. The global SNP...

MEI Pharma, Inc. , a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company’s succession planning, Brian... | June 13, 2023

Global Cell-Free DNA (cfDNA) Testing Market Forecast to 2027 The research Cell-Free DNA (cfDNA) Testing Market report assesses the market dynamics, ma

Einstein's aphorism that doing the same thing over and over again and expecting a different outcome is a hallmark of madness (or at least an inability to learn from the past) inevitably...